Skip to content
Subscriber Only

Alexz Rises on European Union Backing for Bipolar Drug

Alexza Pharmaceuticals Inc. gained the most in four months after the European Union drug regulator recommended the company’s schizophrenia and bipolar disorder medicine for approval.

Alexza, based in Mountain View, California, rose 11 percent to $5.84 at the close in New York, the biggest single-day gain since August. The company fell 37 percent this year before today.